Breo Ellipta (fluticasone furoate/vilanterol)

pCPA File Number: 20832

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Obstructive Pulmonary Disease (COPD)

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

SR0358-000

pCPA Engagement Letter Issued:

2014-10-06

Negotiation Process Concluded:

2015-02-03